BETHLEHEM, Pa., Oct. 10, 2012 /PRNewswire/ -- Particle Sciences, a leading drug delivery CRO, has been selected to be the formulation arm of an effort to create next generation vaginal drug delivery system. Referred to as MOTIF (Microbicide Optimization Through Innovative Formulation), the grant is funded by the European Commission as part of the Seventh Framework Programme. Under the contract, Particle Sciences will develop approaches that allow for multiple actives to be easily incorporated into the same formulation.
Other members of the consortium include King’s College London, Microbiotec, University of Siena, University if Aberdeen, CEA Paris and Imperial College.
In addition to formulation approaches, a major goal of the work is to identify vaginal drug transporters and their impact on topically applied antiretrovirals.
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visitwww.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.
Contact:
Maureen Mattera
1-610-861-4701 x23
mmattera@particlesciences.com
SOURCE Particle Sciences
